OuYang Pu-Yun, Zhang Lu-Ning, Xiao Yao, Lan Xiao-Wen, Zhang Xiao-Min, Ma Jun, Xie Fang-Yun
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Oral Oncol. 2017 Apr;67:37-45. doi: 10.1016/j.oraloncology.2017.01.009. Epub 2017 Feb 7.
We have attempted to validate two published nomograms in nasopharyngeal carcinoma (NPC) and individualize induction chemotherapy (IC) accordingly.
From 2007 to 2011, 920 patients were included in the study. The validity of the nomograms was assessed by Harrell's concordance index (C-index), areas under the curve (AUC), and calibration curves. Disease-free survival (DFS) and overall survival (OS) by IC were evaluated in and out of risk stratified patients with and without propensity score matching analysis.
Compared with the 7th edition of the Union for International Cancer Control (UICC) staging system, Tang's nomogram better discriminated DFS (C-index 0.629 versus 0.569, P=0.002; AUC 0.635 versus 0.576, P=0.018), whereas Yang's nomogram had no advantage in predicting OS (C-index 0.648 versus 0.606, P=0.184; AUC 0.643 versus 0.604, P=0.157). Calibration curves indicated good agreement between predicted and observed DFS or OS probability. Without risk stratification, patients achieved no benefit from IC in DFS (P⩾0.101) or OS (P⩾0.370). However, among 580 high-risk patients stratified by Tang's nomogram, IC improved five-year DFS from 68.8 to 74.8% (P=0.072), and OS from 82.6 to 87.9% (P=0.065), and the improvement of DFS and OS increased to 9.3% (P=0.019) and 7.3% (P=0.036), respectively, in 426 propensity-matched patients.
Tang's nomogram helps to stratify stage III-IVa-b NPC, and IC is beneficial to high-risk patients in clinical practice.
我们试图验证已发表的两种鼻咽癌(NPC)列线图,并据此实现诱导化疗(IC)的个体化。
2007年至2011年,920例患者纳入本研究。列线图的有效性通过Harrell一致性指数(C指数)、曲线下面积(AUC)和校准曲线进行评估。通过倾向评分匹配分析,对风险分层患者进行和未进行IC的无病生存期(DFS)和总生存期(OS)进行评估。
与国际癌症控制联盟(UICC)第7版分期系统相比,Tang列线图对DFS的区分度更好(C指数0.629对0.569,P = 0.002;AUC 0.635对0.576,P = 0.018),而Yang列线图在预测OS方面没有优势(C指数0.648对0.606,P = 0.184;AUC 0.643对0.604,P = 0.157)。校准曲线表明预测的和观察到的DFS或OS概率之间具有良好的一致性。未进行风险分层时,患者在DFS(P≥0.101)或OS(P≥0.370)方面未从IC中获益。然而,在根据Tang列线图分层的580例高危患者中,IC使五年DFS从68.8%提高到74.8%(P = 0.072),OS从82.6%提高到87.9%(P = 0.065),在426例倾向匹配患者中,DFS和OS的改善分别增加到9.3%(P = 0.019)和7.3%(P = 0.036)。
Tang列线图有助于对III-IVa-b期NPC进行分层,在临床实践中IC对高危患者有益。